Nirogacestat not checked
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · PF-03084014
FollowEvery change as it happens, and a Monday email
Trials
2 active
6 in total · 2 in the EU
What this is
- How it works
- Gamma Secretase Inhibitor FDA class
- Tested for
- Desmoid Tumor (2 trials), Aggressive Fibromatosis (2 trials)
- Main trialPhase 4
- “This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.”In the company’s words, NCT07176689 on ClinicalTrials.gov
- Other names
- PF-03084014 · Ogsiveo
Other drugs for Desmoid Tumor
- VaregacestatImmunome, Inc. · Phase 2/3
- FOG-001Parabilis Medicines, Inc. · Phase 1/2
- ES014Elpiscience (Suzhou) Biopharma, Ltd. · Phase 2
- E7386Eisai · Phase 1
- ST316Sapience Therapeutics · Phase 1
Coming up2
- 28 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Feb 2031Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 26 Feb 2031 | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | |
| Phase 2Active, not recruiting | 28 May 2027 | A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) | |
| Phase 3Completed | 7 Apr 2022 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | |
| Phase 2Completed | 8 Jul 2025 | Nirogacestat in Ovarian Granulosa Cell Tumors | |
| Phase 1Completed | 10 Nov 2025 | Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat | |
| Phase 1Completed | 27 Mar 2026 | To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026